Business Development

Current Partnerships



ARCA and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration agreement to support the Phase 2B portion of GENETIC-AF, ARCA’s Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. Medtronic is a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders.

ARCA’s founding scientists are affiliated with the University of Colorado, and important biotechnology that is under development by ARCA had its origins in University Laboratories. ARCA is proud of its longstanding partnership and licensing agreement with the University.


ARCA biopharma is dedicated to establishing mutually beneficial long-term relationships with our partners to improve the health of patients around the world. Please contact:

Chris Ozeroff at for business development and partnering inquiries.
ARCA ©2014 ARCA biopharma | Home | Site Map | Legal Disclaimer